GlassScriptPhysician profile
Jin M Kim
NPI 1871693267
$2,279.81
in general payments reported to CMS, 2019-2025
20 companies · $304 in 2025
The $304 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $398 · 2020: $233 · 2021: $453 · 2022: $262 · 2023: $394 · 2024: $236 · 2025: $304.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $934.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $933.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $360.19 | 2019-2025 | Jardiance |
| Lilly USA, LLC | $339.37 | 2019-2025 | Kisunla |
| Abbvie INC. | $238.77 | 2021-2024 | |
| Allergan, INC. | $162.60 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $147.84 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $129.11 | 2019-2025 | Farxiga |
| Amgen INC. | $128.76 | 2023-2025 | Repatha, Krystexxa, Evenity |
| Pfizer INC. | $127.47 | 2022-2025 | |
| Glaxosmithkline, LLC. | $119.71 | 2019-2025 | Trelegy Ellipta |
| Janssen Pharmaceuticals, INC | $91.30 | 2021-2022 | |
| Abbott Laboratories | $87.30 | 2023 | Freestyle Libre 2, Freestyle Libre 3 |
| Novo Nordisk INC | $81.92 | 2022-2023 | Ozempic, Rybelsus |
| Takeda Pharmaceuticals U.S.A., INC. | $73.43 | 2021-2022 | |
| Exact Sciences Corporation | $46.85 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Gilead Sciences, INC. | $46.39 | 2025 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $31.87 | 2019-2021 | |
| Phadia US INC. | $22.43 | 2024 | Immunocap |
| Eisai INC. | $17.68 | 2021 | |
| Clarus Therapeutics INC. | $14.58 | 2021 | |
| Sun Pharmaceutical Industries INC. | $12.24 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jin Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.